Neurocrine Biosciences presents new data highlighting functional and socio-emotional improvements with INGREZZA® (valbenazine) capsules in individuals with Tardive Dyskinesia and intellectual and developmental disabilities
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity, as well as improvements… read more.
